Site iconSite icon MARKET NEWS

NATCO Pharma Shares Tumble 19% After Q3 Profit Declines 37% YoY

NATCO Pharma Shares Tumble 19% After Q3 Profit Declines 37% YoY
NATCO Pharma Shares Tumble 19% After Q3 Profit Declines 37% YoY

Key Highlights:

Q3 Financial Performance Overview

NATCO Pharma shares opened significantly lower on Thursday, reacting to the company’s weaker-than-expected Q3 results. The 37.75% YoY decline in net profit to ₹132.4 crore was primarily due to a steep drop in formulation exports.

Total expenses fell to ₹487.4 crore, down from ₹539.3 crore in the same period last year. Despite the decline in exports, the company saw growth in API revenue, which rose to ₹66.6 crore from ₹46.3 crore YoY.

Stock Performance & Analyst Outlook

What’s Next for NATCO Pharma?

✔ Dividend Declaration: The company’s board has announced a third interim dividend of ₹1.50 per share for FY 2024-25.
✔ Analyst View: As per Trendlyne, the average target price for NATCO Pharma is ₹1,349, reflecting an 11% potential upside.
✔ Consensus Rating: Out of 11 analysts, the majority recommend a ‘Hold’ on the stock.

Conclusion

NATCO Pharma’s sharp drop in Q3 profit has triggered a sell-off, but analysts remain cautiously optimistic about the stock’s long-term potential. Investors should keep an eye on upcoming earnings, formulation export trends, and broader pharmaceutical sector movements before making any investment decisions.

NEWS SOURCE BY :- GOOLE NEWS

ALSO SEE THIS NEWS:- India Securities Transaction Tax Revenue Rises by 65%

Exit mobile version